Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Intervacc and the Karolinska Institutet extends contract for the development of innovative animal health vaccines
Stockholm, August 15, 2024 –Intervacc AB (publ) and the Karolinska Institute, KI, announce that they have extended their collaboration to develop a new generation of animal health vaccines using recombinant fusion proteins. The three-year extension means that the...Reduction of share capital registered by the Swedish Companies Registration Office
Stockholm, July 31, 2024 – Intervacc AB (publ) announces that the reduction of share capital and nominal value, decided by the Annual General Meeting on May 15, 2024, has been registered by the Swedish Companies Registration Office. After registration, the...Report from Annual General Meeting in Intervacc
Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on Wednesday 15 May 2024, at which the following resolutions were made. Adoption of the income statement and balance sheet The AGM adopted the Board of Directors’ submitted income statement and balance...Interim report January – March 2024
The Group in summary 01/01/24 01/01/23 01/01/23 -31/03/24 -31/03/23 -31/12/23 Net sales 2 394 1 483 8 015 Operating result -17 979 -17 441 -93 579 Result after financial items -17 389 -17 476...Notice of Annual General Meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 15 May 2024 at 1.00 p.m. at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. The Board of Directors has...Nyhetstjänster
